Consolidated Balance Sheets (USD $) In Millions, unless otherwise specified	Dec. 31, 2014		Dec. 31, 2013
Current Assets
Cash and cash equivalents (variable interest entity restricted - 2014: $1)	$ 780		$ 984
Trade receivables - third party and affiliates (net of allowance for doubtful accounts - 2014: $9; 2013: $9)	801		867
Non-trade receivables, net	241		343
Inventories	782		804
Deferred income taxes	29		115
Marketable securities, at fair value	32		41
Other assets	33		28
Total current assets	2,698		3,182
Investments in affiliates	876		841
Property, plant and equipment (net of accumulated depreciation - 2014: $1,816; 2013: $1,672; variable interest entity restricted - 2014: $535)	3,733		3,425
Deferred income taxes	253		289
Other assets (variable interest entity restricted - 2014; $24)	377		341
Goodwill	749	[1]	798
Intangible assets, net	132		142
Total assets	8,818		9,018
Current Liabilities
Short-term borrowings and current installments of long-term debt - third party and affiliates	137		177
Trade payables - third party and affiliates	757		799
Other liabilities	432		541
Deferred income taxes	7		10
Income taxes payable	5		18
Total current liabilities	1,338		1,545
Long-term debt	2,608		2,887
Deferred income taxes	141		225
Uncertain tax positions	159		200
Benefit obligations	1,211		1,175
Other liabilities	283		287
Commitments and Contingencies
Stockholders' Equity
Preferred stock, $0.01 par value, 100,000,000 shares authorized (2014 and 2013: 0 issued and outstanding)	0		0
Treasury stock, at cost (2014: 13,266,625 shares; 2013: 8,928,137 shares)	(611)		(361)
Additional paid-in capital	103		53
Retained earnings	3,491		3,011
Accumulated other comprehensive income (loss), net	(165)		(4)
Total Celanese Corporation stockholders' equity	2,818		2,699
Noncontrolling interests	260		0
Total equity	3,078		2,699
Total liabilities and equity	8,818		9,018
Series A common stock, $0.0001 par value, 400,000,000 shares authorized (2014: 166,169,335 issued and 152,902,710 outstanding; 2013: 165,867,965 issued and 156,939,828 outstanding)
Stockholders' Equity
Common stock	0		0
Series B common stock, $0.0001 par value, 100,000,000 shares authorized (2014 and 2013: 0 issued and outstanding)
Stockholders' Equity
Common stock	$ 0		$ 0

[1] There were $0 million of accumulated impairment losses as of December 31, 2014.